LEXINGTON, Mass., Oct. 9, 2015 /PRNewswire/ -- Pulmatrix,
Inc., (NASDAQ: PULM) will be webcasting the Company's investor
presentation at two upcoming investor conferences.
Pulmatrix will be presenting at the Dawson James 2015 Small Cap
Growth Stock Conference on Thursday, October
15, 2015 at 8:30 am EDT.
Additionally, the Company will be presenting at the 14th
Annual BIO Investor Forum on Tuesday,
October 20, 2015 at 11:00 am
PDT (2:00 pm EDT).
A live webcast of the presentations may be accessed in the
investors section of the Company's website at
www.pulmatrix.com. A replay of the presentations will be
available on the Company's website for 90 days following the
presentation.
About Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company
developing innovative inhaled therapies to address serious
pulmonary disease using its patented iSPERSE™ technology. The
Company's proprietary product pipeline is focused on advancing
treatments for rare diseases, including PUR1900, an inhaled
anti-fungal for patients with cystic fibrosis (CF), as well as
PUR1500, an inhaled product for the treatment of idiopathic
pulmonary fibrosis. In addition, Pulmatrix is pursuing
opportunities in major pulmonary diseases through collaborations,
including PUR0200, a branded generic in clinical development for
chronic obstructive pulmonary disease (COPD). Pulmatrix's
product candidates are based on iSPERSE™, its proprietary dry
powder delivery platform, which seeks to improve therapeutic
delivery to the lungs by maximizing local concentrations and
reducing systemic side effects to improve patient outcomes.
Investor
Contact
|
Media
Contact
|
Tom Baker
Direct:
617-532-0624
tbaker@pulmatrix.com
|
David Schull, Russo
Partners
Direct: (858)
717-2310
David.Schull@russopartnersllc.com
|
Logo -
http://photos.prnewswire.com/prnh/20150616/223308LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/pulmatrix-to-webcast-investor-presentation-at-upcoming-investor-conferences-300157231.html
SOURCE Pulmatrix, Inc.